METAVIA INC (MTVA) Stock Price, Forecast & Analysis
NASDAQ:MTVA • US64132R5037
MTVA Key Statistics, Chart & Performance
The current stock price of MTVA is 1.51 USD. In the past month the price decreased by -36.02%. In the past year, price decreased by -90.6%.
MTVA Technical Analysis
MTVA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTVA. MTVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MTVA Financial Highlights
Over the last trailing twelve months MTVA reported a non-GAAP Earnings per Share(EPS) of -13.9. The EPS increased by 78.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.83% | ||
| ROE | -256.14% | ||
| Debt/Equity | 0 |
MTVA Forecast & Estimates
9 analysts have analysed MTVA and the average price target is 92.82 USD. This implies a price increase of 6047.02% is expected in the next year compared to the current price of 1.51.
MTVA Ownership
MTVA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MTVA
Company Profile
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Company Info
METAVIA INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS US
Employees: 9
Phone: 18577029600
METAVIA INC / MTVA FAQ
What does MTVA do?
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
What is the stock price of METAVIA INC today?
The current stock price of MTVA is 1.51 USD. The price decreased by -5.03% in the last trading session.
Does METAVIA INC pay dividends?
MTVA does not pay a dividend.
How is the ChartMill rating for METAVIA INC?
MTVA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MTVA stock?
MTVA stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for METAVIA INC?
METAVIA INC (MTVA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for METAVIA INC?
METAVIA INC (MTVA) has a market capitalization of 4.85M USD. This makes MTVA a Nano Cap stock.